5/21
08:03 am
ikt
Inhibikase Therapeutics, Inc. (NYSE: IKT) had its price target lowered by analysts at HC Wainwright from $27.00 to $23.00. They now have a "buy" rating on the stock.
Low
Report
Inhibikase Therapeutics, Inc. (NYSE: IKT) had its price target lowered by analysts at HC Wainwright from $27.00 to $23.00. They now have a "buy" rating on the stock.
5/20
08:12 am
ikt
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million [Yahoo! Finance]
High
Report
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million [Yahoo! Finance]
5/20
08:01 am
ikt
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
Medium
Report
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
5/15
08:14 pm
ikt
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity [Yahoo! Finance]
High
Report
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity [Yahoo! Finance]
5/15
08:00 pm
ikt
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
High
Report
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
5/15
08:47 am
ikt
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement [Yahoo! Finance]
High
Report
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement [Yahoo! Finance]
5/15
08:45 am
ikt
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
High
Report
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
5/9
08:12 am
ikt
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension [Yahoo! Finance]
Medium
Report
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension [Yahoo! Finance]
5/9
08:00 am
ikt
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
Medium
Report
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
4/18
04:45 pm
ikt
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs [Yahoo! Finance]
Low
Report
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs [Yahoo! Finance]
4/18
04:30 pm
ikt
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Low
Report
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
4/3
08:24 am
ikt
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension [Yahoo! Finance]
High
Report
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension [Yahoo! Finance]
4/3
08:05 am
ikt
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
Medium
Report
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
4/2
10:40 am
ikt
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
04:24 pm
ikt
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity [Yahoo! Finance]
Medium
Report
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity [Yahoo! Finance]
3/27
04:15 pm
ikt
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
Medium
Report
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
3/7
08:41 am
ikt
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders [Yahoo! Finance]
Low
Report
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders [Yahoo! Finance]
3/7
08:30 am
ikt
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Medium
Report
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
3/5
11:02 am
ikt
Inhibikase Therapeutics, Inc. (NYSE: IKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Medium
Report
Inhibikase Therapeutics, Inc. (NYSE: IKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.